Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Inhibiting STAT1 Signaling and MHC Class I Expression.
Journal: The Journal of clinical investigation
Published: August 13, 2026
Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial.
Journal: Journal of psychosocial oncology
Published: April 08, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Journal: Nature communications
Published: February 06, 2026
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED): A single-arm phase 2 trial.
Journal: Cancer
Published: July 16, 2025
ASO Author Reflections: Towards Personalized Cancer Therapy: The Role of ctDNA as a Biomarker in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion.
Journal: Annals of surgical oncology
Published: June 27, 2025
Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion.
Journal: Annals of surgical oncology
Published: April 21, 2025
Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective.
Journal: Annals of surgical oncology
Published: January 10, 2025
Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated esophagogastric cancer patients predicts clinical responses.
Journal: Research square
Published: January 07, 2025
ASO Author Reflections: Expansion of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Colorectal Liver Metastases.
Journal: Annals of surgical oncology
Published: November 20, 2024
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 21, 2024
Last Updated: 09/26/2026